ArticleCureus2025
Analysis of Risk Scoring for Placenta Accreta Spectrum and Its Impact on Maternal and Fetal Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlacenta accreta spectrum (PAS) disorders, characterized by abnormal adherence or invasion of the placenta into the myometrium, are associated with significant maternal and neonatal morbidity. Early identification of high-risk cases is essential to optimize delivery planning and reduce adverse outcomes. The Placenta Accreta Index (PAI), integrating clinical history and ultrasound parameters, has been proposed as a predictive tool for PAS. This study aimed to evaluate the diagnostic accuracy of the PAI in predicting PAS and its utility in anticipating maternal and neonatal outcomes. MATERIALS AND
methodsA prospective observational study was conducted on 150 pregnant women at risk for PAS. A single experienced sonographer performed all ultrasound evaluations and PAI scoring to minimize observer bias. The PAI incorporated the number of prior cesarean sections, placental lacunae grade, sagittal myometrial thickness, anterior placenta previa, and bridging vessels. A standardized management protocol was followed: antenatal corticosteroids for fetal lung maturity, magnesium sulfate for neuroprotection when <34 weeks, and multidisciplinary team involvement (obstetricians, anesthetists, neonatologists, and blood bank). MRI or Doppler studies were used selectively to confirm placental invasion depth, and delivery timing (34-36 weeks or earlier for antepartum bleeding) was guided by imaging and clinical stability. Intraoperative findings and histopathological examination (HPE) served as reference standards. Maternal and neonatal outcomes were recorded.
resultsAmong 150 participants, the placenta was posterior in 84 (56%), anterior in 33 (22%), low-lying in 18 (12%), and fundal in 15 (10%). Placental lacunae were most commonly Grade 2 (49, 32.7%), and myometrial thickness <1 mm was observed in 58 (38.7%). Placenta previa was present in 105 (70%) women. HPE findings revealed a normal placenta in 142 (94.7%), absence of decidua with thin Nitabuch's layer in 4 (2.7%), thin Nitabuch's layer in 3 (2%), and villi directly contacting myometrium in 1 (0.7%). The PAI demonstrated sensitivity 100% (95% CI: 2.5-100), specificity 97.3% (95% CI: 92.8-99.2), positive predictive value 20% (95% CI: 3.6-62.4), negative predictive value 100%(95% CI: 97.4-100), and overall diagnostic accuracy 97.3% (95% CI: 92.9-99.2). Maternal outcomes were favourable in 145 (96.7%) cases; one woman (0.7%) required hysterectomy, and four (2.7%) had excessive bleeding managed conservatively.
conclusionsPAI is a reliable, non-invasive tool for identifying women at high risk for PAS. High PAI scores can guide prenatal counselling, delivery planning, and resource allocation, while low scores effectively rule out severe placental invasion, supporting safer conservative management. The use of PAI may have the potential to improve maternal and neonatal outcomes in pregnancies complicated by PAS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.